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Myeloid DCs (mDCs) and plasmacytoid pre-
DCs (pDCs) represent two major subsets of 
DCs in humans (1, 2). mDCs selectively express 
Toll-like receptor (TLR) 2–6 and 8 and have 
the ability to produce large amounts of IL-12 
during antibacterial and antiviral responses, 
whereas pDCs express TLR7 and TLR9 and 
have the ability to produce large amounts of 
type 1 IFNs in antiviral immune responses 
(3–5). The ability of pDCs to rapidly produce 
large amounts of type 1 IFNs upon endosomal 
TLR7 and TLR9 activation has been linked 
to their unique and constitutive expression of 
IRF7 (6), the ability to rapidly form Myd88–
IRAK1–IRAK4–TRAF6–IRF7 signal trans-
duction complexes (7), and the unique nature 
of the endosome allowing prolonged retention 
of microbial-derived RNA and DNA (8). 
These fi   ndings have provided the functional 
and molecular basis for the concept that mDCs 
and pDCs play distinct and complementary 
roles in innate antimicrobial immunity.
mDCs and pDCs also play distinct roles in 
the regulation of T cell–mediated adaptive im-
munity (9, 10). However, the functional plas-
ticity of both DC subsets coupled with the lack 
of a direct molecular mechanism to explain 
these diff  erences has made it diffi   cult to draw a 
defi  nitive conclusion regarding the concept of 
functional DC subsets.
Previously, it has been shown that mDCs 
at an immature stage have the ability to prime 
  naive T cells to diff  erentiate into IL-10–pro-
ducing T regulatory cells (11–13). Conversely, 
mDCs matured by microbial ligands for TLRs 
or by CD40 ligand (CD40L) prime naive T cells 
to diff   erentiate into T helper (Th)1 eff  ector 
cells (9, 14). Paradoxically, pDCs appear to have 
an intrinsic capacity to prime naive T cells to 
diff  erentiate into IL-10–producing T regulatory 
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cells at a mature stage either activated by IL-3 plus CD40L or 
by TLR9 ligands (15, 16).
In this study, we identify the molecular mechanism under-
lying this phenomenon. We found that in contrast to matur-
ing mDCs, maturing pDCs rapidly and strongly up-regulate 
  inducible costimulator (ICOS) ligand (ICOS-L) and specifi  -
cally drive the generation of IL-10–producing T regula  tory 
cells regardless of the activation pathway. Our fi  ndings   provide 
the molecular evidence that pDCs are diff  erent from mDCs 
in regulating T cell–mediated adaptive immune   responses 
Figure 1.  ICOS-L is preferentially expressed by activated pDCs 
and not mDCs. Microarray gene expression profi  les of B7-like molecules 
B7-H1, ICOS-L, B7-H3, and B7-DC in freshly isolated unstimulated (unstim) 
pDCs and pDCs activated by different stimuli in comparison with freshly 
isolated unstimulated mDCs, mDCs activated by different stimuli, and 
other primary immune cells of the blood. Results of the gene expression 
profi  les are shown as the relative gene hybridization intensity level.
Figure 2.  In contrast to mDCs, pDCs up-regulate ICOS-L upon 
activation and maintain high expression levels upon differentiation 
into mature DCs. (A) Surface expression of ICOS-L, CD80, and CD86 in 
freshly isolated untreated pDCs and pDCs activated along the IL-3–
  dependent pathway with IL-3 plus CD40L for 6 d or along the TLR-
  dependent pathway with CpG-B, CpG-A, or HSV for 1 d. Open histograms 
represent staining of costimulatory molecules; closed histograms repre-
sent isotype controls. (B) Mean fl  uorescence intensity of ICOS-L and CD86 
expression in pDCs activated by CpG-B monitored at different points over 
a 48-h period of maturation into DCs. (C) Surface expression of ICOS-L, 
CD80, and CD86 on blood monocytes (Mono), monocyte-derived DCs 
cultured for 5 d with GM-CSF and IL-4 (immature mDC), and mature 
mDCs activated along the CD40L pathway (CD40L-mDC) or the TLR-
  dependent pathway (LPS-mDC). Results in A–C are representative of at 
least fi  ve independent experiments.JEM VOL. 204, January 22, 2007  107
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through their intrinsic ability to up-regulate ICOS-L and in-
duce IL-10–producing T regulatory cells after diff  erentiation 
into mature DCs.
RESULTS
pDCs but not mDCs preferentially up-regulate ICOS-L 
upon activation
Recently identifi   ed B7-like molecules, including B7-H1, 
ICOS-L, B7-H3, and B7-DC, have been shown to costimu-
late T cells for IL-10 production (17–20). To test whether a 
distinct expression pattern of these B7-like molecules deter-
mines the capacity of maturing pDCs but not maturing 
mDCs to generate IL-10–producing T cells, we compared 
microarray gene expression profi  les of B7 superfamily mem-
bers in pDCs and mDCs activated in culture by a variety of 
stimuli. Maturing pDCs and maturing mDCs strongly up-
regulated the expression of the classic costimulatory  molecules 
CD80 and CD86 (not depicted). However,   compared with 
maturing mDCs, maturing pDCs preferentially up-  regulated 
the expression of ICOS-L but not B7-H1, B7-H3, B7-DC 
(Fig. 1), or B7-H4 (undetectable; not   depicted). 
Strong ICOS-L expression on activated pDCs is maintained 
upon differentiation into mature DCs along both 
TLR- and IL-3/CD40L-dependent pathways
To confi  rm the gene expression data and gain further insights 
into the regulation of ICOS-L during pDC maturation, we 
performed fl   ow cytometry for surface ICOS-L expression. 
Freshly isolated blood pDCs constitutively expressed ICOS-L 
(log 1 fl  uorescence intensity) while lacking CD80 and express-
ing minimal levels of CD86 (Fig. 2 A) as previously reported 
(21). pDCs stimulated with IL-3 plus CD40L gradually up-
regulated CD80 and CD86 expression and became fully ma-
ture DCs within 6 d of culturing. In contrast, the up-regulation 
of ICOS-L was very strong and occurred very rapidly (reaching 
log 2–3 fl  uorescence intensity within the fi  rst 24 h of culturing; 
Fig. 2 A). Importantly, the high levels of ICOS-L expression 
persisted during the 6-d process of DC maturation (Fig. 2 A).
Similarly, pDCs stimulated with three TLR9 agonists, 
CpG-A, CpG-B, and HSV, up-regulated ICOS-L expression 
very strongly (log 2–3 fl  uorescence intensity) within the fi  rst 
24 h of culturing (Fig. 2 A). However, of the TLR9 agonists, 
only CpG-B considerably up-regulated CD80 and CD86 ex-
pression within 24 h of stimulation. The dissociation between 
the expression of ICOS-L and the expression of CD80 and 
CD86 was further confi  rmed by a time-course analysis of 
pDC stimulated with CpG-B. Whereas maximal ICOS-L 
expression levels were reached within 12 h of stimulation, the 
up-regulation of CD80 and CD86 was a gradual process 
reaching its maximum after 48 h (Fig. 2 B). As was the case in 
pDCs matured by IL-3 and CD40L, the high ICOS-L ex-
pression persisted during the 48-h maturation process of 
CpG-B–stimulated pDCs. These data indicate that irrespec-
tive of the nature of the activation stimulus, pDCs rapidly ex-
press high levels of ICOS-L and maintain the expression after 
diff  erentiation into fully mature DCs.
Unlike pDCs, mDCs down-regulate the expression of ICOS-L 
on maturation
Next, we investigated the regulation of ICOS-L expression 
in monocyte-derived DCs as a model system for mDCs. 
ICOS-L was not expressed by freshly isolated blood mono-
cytes and was expressed at low levels in monocyte-derived 
immature mDCs induced by IL-4 and GM-CSF (log 1 fl  uo-
rescence intensity; Fig. 2 C). Activation of immature mDCs 
by CD40L or TLR4 ligand LPS strongly up-regulated the 
expression of CD80 and CD86 but down-regulated ICOS-L 
expression (Fig. 2 C; reference 11). Thus, whereas both ma-
turing pDCs and maturing mDCs expressed high levels of 
CD80 and CD86, maturing pDCs but not maturing mDCs 
express high levels of ICOS-L. This diff  erence is not depen-
dent on the nature of the activation stimulus (TNF-R– vs. 
TLR-mediated activation) but may refl  ect an intrinsic diff  er-
ence between pDCs and mDCs.
Maturing pDCs use ICOS-L to induce the differentiation 
of naive CD4 T cells into IL-10–producing T cells during 
Th1 and Th2 responses
Because ICOS-L has been previously linked to the induction 
of IL-10 (22–24), we sought to determine whether ICOS-L 
on maturing pDCs is required for the diff  erentiation of naive 
T cells into IL-10–producing T cells. Maturing pDCs gener-
ated in culture with CpG-B (named CpG-pDC) or IL-3 plus 
CD40L (named IL-3/CD40L-pDC) and maturing mDCs 
activated by CD40L (named CD40L-mDC) were cultured 
with allogeneic peripheral blood–derived naive CD4 T cells. 
We found that ICOS was expressed at very low levels on   naive 
T cells but was substantially induced within 1 d of   culturing 
Figure 3.  Both maturing mDCs and pDCs use CD28 costimulation 
to expand naive T cells. Naive peripheral CD4 T cells were cocultured 
with IL-3/CD40L-pDCs, CpG-pDCs, or CD40L-mDCs in the presence of 
neutralizing antibodies against ICOS-L (anti–ICOS-L) and against CD80 
plus CD86 (anti-CD80/86) or were cocultured with isotype-matched con-
trol antibodies (−). After 6 d of culturing, T cell numbers were measured 
using trypan blue exclusion, and the T cell expansion was calculated. 
Each symbol represents an independent experiment, and horizontal bars 
represent the mean. P-values calculated by unpaired Student’s t test 
are indicated.108  PLASMACYTOID DENDRITIC CELLS AND ICOS-L | Ito et al.
with maturing pDCs and mDCs, reaching maximal expres-
sion levels within 4 d (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20061660/DC1). To determine a 
role for ICOS-L in these primary cultures, we blocked ICOS 
costimulation by neutralizing mAbs against ICOS-L in com-
parison with a CD28 blockade by neutralizing mAbs against 
CD80 plus CD86. CpG-pDCs, IL-3/CD40L-pDCs, and 
CD40L-mDCs all induced strong expansion of naive T 
cells that was largely blocked by neutralizing mAbs against 
CD80 and CD86 but not against ICOS-L, confi  rming that 
CD28 is the most prominent costimulatory pathway for the 
DC-mediated expansion of naive T cells (Fig. 3). However, 
we observed that blocking ICOS costimulation signifi  cantly 
enhanced the expansion of naive T cells in cultures with 
CpG-pDCs and IL-3/CD40L-pDCs but not CD40L-mDCs, 
suggesting a role for ICOS-L in primary T cell activation by 
maturing pDCs (Fig. 3).
To determine whether ICOS-L on maturing pDCs is in-
volved in the polarization of naive T cells, we tested the abil-
ity of primed T cells to secrete cytokines in response to a 
polyclonal restimulation. T cells primed by CpG-pDCs 
produced large amounts of IL-10 (800–6,400 pg/ml; n = 6), 
Figure 4.  Maturing pDCs but not mDCs use ICOS-L to specifi  cally 
generate T cells producing IL-10 during the induction of both Th1 
and Th2 responses. Peripheral naive CD4 T cells were cocultured with 
CpG-pDCs, IL-3/CD40L-pDCs, LPS-mDCs, and CD40L-mDCs in the pres-
ence of neutralizing antibodies against ICOS-L (anti–ICOS-L), CD80 plus 
CD86 (anti-CD80/86), or isotype-matched control antibodies (−). (A) The 
ability of primed T cells to secrete IL-10, -4, -5, -13, IFN-γ, and TNF-α was 
assayed by ELISA of supernatants collected 24 h after polyclonal stimula-
tion with anti-CD3 and -CD28 mAbs. The results are representative of six 
independent experiments. < indicates that the measured value was below 
the detection limit of the assay experiments (<20 pg/ml). T cells primed 
by LPS-mDCs (not depicted) secreted an equivalent cytokine profi  le as 
T cells primed by CD40L-mDCs. Error bars represent SD. (B) Intracellular 
production of IL-10 and IFN-γ assayed by fl  ow cytometry 6 h after the 
stimulation of primed T cells with PMA and ionomycin. The percentages 
of each population are indicated in the plots. One of three independent 
experiments is shown.JEM VOL. 204, January 22, 2007  109
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moderate levels of IFN-γ and TNF-α, but no IL-4, -5, or 
-13 (Fig. 4 A). This cytokine profi  le is consistent with a Th1-
like response as previously reported (25). The blocking of 
ICOS costimulation by neutralizing anti–ICOS-L mAbs sig-
nifi  cantly inhibited the production of IL-10 (mean reduction 
of 74 ± 14%; P < 0.01) but not of IFN-γ or TNF-α (Fig. 4 A). 
In contrast, blocking CD28 costimulation by neutralizing 
anti-CD80 and -CD86 mAbs led to an increased production 
of IL-10 (mean increase of 40 ± 17%; P < 0.01) but not of 
IFN-γ or TNF-α (Fig. 4 A). T cells primed with IL-3/
CD40L-pDCs produced large amounts of IL-10 (900–7,500 
pg/ml; n = 6), substantial levels of IL-4, -5, and -13, and 
moderate levels of IFN-γ and TNF-α (Fig. 4 A). This cyto-
kine profi  le is consistent with a Th2-type response as previ-
ously reported (9). Blocking ICOS costimulation signifi  cantly 
inhibited the production of IL-10 (mean reduction of 80 ± 
10%; P < 0.01) but did not inhibit the production of IL-4, -5, 
or -13 nor IFN-γ or TNF-α (Fig. 4 A). In contrast, blocking 
CD28 costimulation led to an increased production of IL-10 
(mean increase of 27 ± 12%; P < 0.01) while inhibiting the 
production of IL-4, -5, -13 (>70% reduction for all cytokines), 
and partially IFN-γ and TNF-α (Fig. 4 A). Confi  rming the 
ELISA data, we found on the single-cell level that the genera-
tion of IL-10–producing T cells from naive CD4 T cells was 
strongly inhibited by anti–ICOS-L mAbs in cultures with 
CpG-pDCs (decrease from 17 to 7% of IL-10–producing T 
cells) and IL-3/CD40L-pDCs (decrease from 11 to 4%) but 
was enhanced by anti-CD80 and -CD86 antibodies in cultures 
with CpG-pDCs (increase from 17 to 25%) and IL3/CD40L-
pDCs (increase from 11 to 23%; Fig. 4 B). Interestingly, over 
two thirds of IL-10–producing T cells coexpressed IFN-γ (Fig. 
4 B), but all IL-10–producing T cells were clearly negative for 
IL-4, -5, or -13 (not depicted). Consistent with their low ex-
pression of ICOS-L, maturing mDCs did not generate detect-
able numbers of IL-10–producing T cells even in the presence 
of anti-CD80 and -CD86 antibodies (Fig. 4, A and B). Impor-
tantly, naive T cells stimulated under neutral conditions by 
anti-CD3 did not produce IL-10, indicating that ICOS-L on 
maturing pDCs drive the de novo generation and not the ex-
pansion of preexisting IL-10–producing T cells (Fig. 5). 
To confi  rm the capacity of ICOS-L on maturing pDCs 
to diff  erentiate truly naive T cells into IL-10–producing T 
cells, we performed additional coculture experiments using 
naive CD4 T cells isolated from cord blood. Maturing pDCs 
primed naive cord blood–derived T cells to produce very 
large amounts of IL-10 (7,000–110,000 pg/ml primed by 
CpG-pDCs,  n  = 3; and 4,000–30,000 pg/ml primed by 
IL-3/CD40L-pDCs, n = 3). The blocking of ICOS costimu-
lation signifi  cantly inhibited the ability of primed T cells to 
produce IL-10 (mean reduction of 60 ± 18%; P < 0.01) but 
not their ability to produce IFN-γ or IL-4 (Fig. S2, available 
at http://www.jem.org/cgi/content/full/jem.20061660/DC1).
Together, these results indicate that maturing pDCs use 
ICOS-L to drive the diff  erentiation of naive T cells into T 
cells producing IL-10 in the context of Th1 and Th2 polar-
ization. Interestingly, the functions of ICOS costimulation 
do not overlap with those of CD28-mediated costimulation. 
Whereas ICOS costimulation is critical for the generation of 
IL-10–producing T cells, CD28 costimulation inhibits the 
generation of these cells but is required for both T cell expan-
sion and production of Th2 cytokines IL-4, -5, and -13 and, 
to some extent, for the production of Th1 cytokines IFN-γ 
and TNF-α. Importantly, the generation of IL-10–producing 
T cells by ICOS-L occurs regardless of the functional plasticity 
of pDCs to induce Th1 or Th2 polarization upon activation 
by a TLR-dependent or IL3/CD40L pathway.
ICOS-L is suffi  cient to drive the generation of IL-10–
producing T cells in the absence of Th2 polarization
Historically, IL-10 has been associated with Th2 cytokines 
IL-4, -5, and -13 (26). However, our neutralization experi-
ments suggested that the induction of IL-10 versus Th2 cyto-
kines may be diff  erentially regulated by ICOS and CD28 
costimulation. To further confi  rm these fi  ndings, we stimu-
lated naive CD4 T cells with anti-CD3 alone or anti-CD3 in 
the presence of ICOS-L and/or CD28 costimulation. Naive 
T cells stimulated by anti-CD3 alone did not diff  erentiate 
to produce IL-10 or -4 (Fig. 5), whereas the addition of 
ICOS-L stimulation generated T cells producing high levels of 
IL-10 but not IL-4, and the addition of CD28 costimulation 
Figure 5.  The generation of IL-10 and IL-4 are differentially regu-
lated by ICOS-L and CD28 costimulation, respectively. Peri pheral 
naive CD4 T cells were cultured for 6 d on parental L cells or ICOSL-L cells, 
which were precoated with 0.2 μg/ml anti-CD3 mAb stimulating 1 μg/ml 
anti-CD28 mAb or isotype-matched control antibodies were added into 
the culture. The ability of primed T cells to secrete IL-10, -4, and IFN-γ 
was assayed by ELISA of supernatants collected 24 h after polyclonal 
  stimulation with anti-CD3 and -CD28 mAbs. The results are representa-
tive of three independent experiments. < indicates that the measured 
value was below the detection limit of the assay (<20 pg/ml). Error bars 
represent SD.110  PLASMACYTOID DENDRITIC CELLS AND ICOS-L | Ito et al.
generated T cells producing substantial levels of IL-4 but not 
IL-10 (Fig. 5). These data indicate that ICOS-L is suffi   cient 
to drive the generation of IL-10–producing T cells in the ab-
sence of Th2 cytokine IL-4 and confi  rm that the generation 
of T cells producing IL-10 versus IL-4 is diff  erentially regu-
lated by ICOS and CD28 costimulation. Furthermore, naive 
T cells stimulated by anti-CD3 alone produced considerable 
levels of IFN-γ that was enhanced by the presence of CD28 
costimulation but not by ICOS-L (Fig. 5), confi  rming that 
ICOS costimulation is not involved in Th1 polarization. 
Similar to what we have described in the blocking experi-
ments, the presence of CD28 costimulation decreased the 
ICOS-L–driven generation of IL-10–producing T cells (Fig. 5).
IL-4 represents a master regulator of Th2 polarization 
(27). To ascertain that IL-4 is not involved in the generation 
of IL-10–producing T cells by maturing pDCs, we performed 
blocking experiments using neutralizing anti–IL-4 mAbs. 
  Although pDCs are unable to produce IL-4 (9), this cytokine 
may originate from developing Th2 cells themselves. Block-
ing of IL-4 partially inhibited the ability of naive T cells 
primed by IL3/CD40L-pDCs to produce Th2 cytokine IL-4, 
but it had no eff  ect on the generation of IL-10–producing 
T cells (Fig. 6). These data suggest that the development of 
IL-10–producing T cells is independently regulated; however, 
we cannot completely rule out the possibility that ICOS-
L–  induced IL-10 may at least in part depend on residual IL-4 
given that anti–IL-4 only partially inhibited Th2 develop-
ment in our culture system with IL3/CD40L-pDCs. Priming 
of naive T cells with CpG-pDCs in the presence of anti–IL-4–
blocking mAbs did not aff  ect IL-10 production, confi  rming 
that the ICOS-L–driven induction of IL-10 can occur in the 
absence of a Th2 response (Fig. 6).
IL-10–producing T cells driven by ICOS-L on maturing pDCs 
are T regulatory cells
Three observations prompted us to determine whether IL- 
10–producing T cells primed by maturing pDCs through 
ICOS costimulation are T regulatory cells. First, the IL-
10+IFN-γ+ T cell profi  le induced by ICOS-L was reminis-
cent of T regulatory type 1 cells (28). Second, the inhibition 
of ICOS costimulation enhanced the ability of maturing 
Figure 6.  Blocking of IL-4 does not inhibit IL-10 induction in Th1 
cells in response to ICOS-L on maturing CpG-pDCs. Peripheral naive 
CD4+ T cells were cocultured with IL-3/CD40L-pDCs or CpG-pDCs in the 
presence of neutralizing antibodies against IL-4 or isotype-matched con-
trol antibodies (−). (A) Intracellular production of IL-10 and IFN-γ (top 
and bottom plots) as well as IL-4 and IFN-γ (middle plots) was assayed by 
fl  ow cytometry 6 h after the stimulation of primed T cells with PMA and 
ionomycin. The percentages of each population are indicated in the plot. 
(B) The ability of primed T cells to secrete IL-10, -4, or IFN-γ was assayed 
by ELISA of supernatants collected 24 h after polyclonal stimulation with 
anti-CD3 and -CD28 mAbs. One representative experiment of four independ-
ent experiments is shown. < indicates that the measured value was below 
the detection limit of the assay (<20 pg/ml). Error bars represent SD.
Figure 7.  IL-10–producing T cells generated by ICOS-L on maturing 
pDCs are anergic. (A) CD4 T cells primed by CpG-pDCs, IL-3/CD40L-
pDCs, LPS-mDCs, and CD40L-mDCs in the presence of neutralizing anti–
ICOS-L mAbs (hatched bars) or isotype-matched control antibodies (black 
bars) were collected after 6 d and reactivated with allogeneic monocytes 
from the same donor whose cells were used for priming. The ability of 
primed T cells to mount a proliferative response was assessed by 
3[H]thymidine incorporation after 2 d. (B) CD4 T cells primed by CpG-pDCs 
in the presence of neutralizing anti–ICOS-L mAbs (hatched bars) or isotype-
matched control antibodies (black bars) were either reactivated by 
  allogeneic monocytes (APC) or low doses of anti-CD3 (1 μg/ml; plate 
bound) plus or minus neutralizing mAbs to IL-10 and -10R. (A and B) 
Results are expressed as mean counts per minute + SD (error bars) of 
triplicate wells and are representative of three independent experiments.JEM VOL. 204, January 22, 2007  111
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pDCs to expand T cells, suggesting that IL-10–producing 
T cells are poorly proliferative, which is a cardinal feature of 
T regulatory cells. Finally, ICOS costimulation has been im-
plicated in the induction of T regulatory cell–mediated pe-
ripheral tolerance (29–31). First, we examined the ability of 
T cells primed with maturing pDCs to proliferate in response 
to an alloantigen-specifi  c reactivation. Both T cells primed 
with CpG-pDCs and IL-3/CD40L-pDCs proliferated poorly 
in response to the reactivation (Fig. 6 A). A mean reduction 
of 80 ± 15% (n = 3) and 70 ± 20% (n = 3) in their prolifera-
tive response was observed compared with T cells primed with 
CD40L-mDCs. In contrast, T cells primed with both CpG-
pDCs and IL-3/CD40L-pDCs in the presence of neutraliz-
ing anti–ICOS-L antibodies proliferated at similar levels to 
CD40L-mDCs in response to the reactivation (Fig. 7 A). 
Given that T cells primed with maturing pDCs produce IL-10, 
we tested whether the reduced proliferation was caused by 
an inhibition of APC function by IL-10 secreted during the 
reactivation. This was not the case because the neutralization 
of IL-10 during the reactivation failed to reverse the low pro-
liferation of T cells primed with maturing pDCs (Fig. 7 B). 
Also, reactivation in an APC-free system by low doses of 
anti-CD3 antibodies failed to reverse the low proliferation of 
T cells primed with maturing pDCs, confi  rming that these 
T cells have the intrinsic anergic phenotype of T regulatory 
cells. ICOS costimulation was required to induce this state of 
anergy because T cells proliferated vigorously if neutralizing 
anti–ICOS-L antibodies were added during priming with 
maturing pDCs (Fig. 7 B).
To determine whether these T cells are immunosuppres-
sive, T cells primed with maturing pDCs were added into a 
coculture of autologous naive T cells with monocytes de-
rived from the original allogeneic donor. T cells primed with 
maturing pDCs strongly inhibited the proliferation of naive 
T cells in a dose-dependent manner (Fig. 8 A). In contrast, 
T cells primed with maturing pDCs in the presence of neutral-
izing anti–ICOS-L failed to do so (Fig. 8 A). To further in-
vestigate whether IL-10 was involved in immunosuppression 
by T regulatory cells primed with maturing pDCs, neutral-
izing antibodies to IL-10 and -10R were added into the 
  cocultures. Anti–IL-10 completely blocked the inhibitory 
eff  ect of these T regulatory cells (Fig. 8 B), indicating that 
the suppression was mediated by IL-10. Accordingly, T cells 
primed with maturing pDCs in the presence of neutralizing 
anti–ICOS-L (which secrete low levels of IL-10) or T cells 
primed with maturing mDCs (which do not secrete any 
IL-10) failed to suppress the proliferation of naive T cells 
(Fig. 8 B). A role of IL-10 in suppression was further con-
fi  rmed by the fi  nding that the inhibitory eff  ect of T cells 
primed with maturing pDCs could be mimicked by the 
  addition of low doses of IL-10 into the cultures (Fig. 8 B). 
Thus, maturing pDCs have the unique ability to generate 
IL-10–producing T regulatory cells through their high 
  expression of ICOS-L. These IL-10–producing T cells are 
anergic and potently suppress bystander T cell responses by 
secreting IL-10.
D  I  S  C  U  S  S  I  O  N 
Although there is evidence for distinct roles of mDCs and 
pDCs in regulating T cell–mediated adaptive immunity, the 
concept of functional DC subsets has been questioned be-
cause of the plasticity of both subsets and the lack of a molec-
ular correlate to explain these diff  erences. Now, we provide 
the direct molecular evidence that maturing mDCs and ma-
turing pDCs are intrinsically distinct in that they express dif-
ferent sets of molecules for T cell priming. Although both 
mDCs and pDCs up-regulate the expression of CD80 and 
CD86 upon activation, only pDCs up-regulate the expression 
Figure 8.  IL-10–producing T cells generated by ICOS-L on maturing 
pDCs are T regulatory cells. (A) The capacity of primed T cells to suppress 
primary T cell responses was tested by stimulating naive CD4+ T cells with 
allogeneic monocytes (APC) in the presence of decreasing numbers 
of syngeneic T cells primed by CpG-pDCs alone (circles) or CpG-pDCs in 
the presence of anti–ICOS-L mAbs (squares). 3[H]thymidine incorporation 
was assessed after 6 d. Results are representative of three independent 
experiments. Importantly, the maximal proliferation of restimulated T cells 
primed with CpG-DCs or CpG-DCs plus anti–ICOS-L alone after 6 d 
was <5,000 cpm. (B) Naive CD4+ T cells were cultured with allogeneic 
monocytes alone (A), monocytes plus T cells primed by CpG-pDCs (B), 
monocytes plus T cells primed by CpG-pDCs in the presence of anti–ICOS-L 
mAbs (C), and monocytes plus T cells primed by maturing mDCs (D). The 
role of IL-10 in the suppressive activity of primed T cells was determined 
by adding anti–IL-10/IL-10R mAbs (anti-IL10/R) or recombinant human 
IL-10 to the suppression assay. The results are representative of fi  ve 
  experiments. Similar to T cells primed by CpG-pDCs, T cells primed 
by IL-3/CD40L-pDCs suppressed primary T cell responses (not depicted). 
(A and B) Results are expressed as mean counts per minute + SD (error bars) 
of triplicate wells.112  PLASMACYTOID DENDRITIC CELLS AND ICOS-L | Ito et al.
of ICOS-L and maintain high expression levels upon diff  er-
entiation into fully mature DCs along both TLR- and IL-3/
CD40L-dependent activation pathways. The high levels of 
ICOS-L expression endow maturing pDCs with a dominant 
costimulatory pathway leading to the diff  erentiation of naive 
CD4 T cells into T cells producing IL-10 but not Th2 cyto-
kines IL-4, -5, and -13 or Th1 cytokines IFN-γ and TNF-α 
during the induction of Th2 and Th1 polarization. In con-
trast, maturing mDCs down-regulate ICOS-L expression 
upon activation by TLR ligands or CD40L and, accordingly, 
fail to induce T cells producing IL-10.
Historically, IL-10 production has been linked to the 
production of Th2 cytokines IL-4, -5, and -13 (26). How-
ever, recent studies have reported that IL-10 is not involved 
in Th2-mediated allergic responses (32, 33) and may even 
inhibit such responses (34). Our study now provides evi-
dence for a distinct regulation of IL-10 and Th2 cytokine 
induced by maturing pDCs. First, we show that IL-10 and 
Th2 cytokines are diff   erentially induced by ICOS-L and 
CD28 costimulation. Blocking ICOS-L on maturing pDCs 
inhibits the specifi  c production of IL-10 without aff  ecting 
the induction of Th2 cytokines IL-4, -5, and -13. Conversely, 
blocking CD28 costimulation inhibits the production of Th2 
cytokines without aff  ecting IL-10. Second, we show that 
TLR-activated pDCs, which inhibit Th2 development and 
drive Th1 polarization through the secretion of type 1 IFNs 
(35), retain the ability to generate IL-10–producing T 
cells. Finally, we show that blocking IL-4, a cytokine that has 
an instructive role in directing Th2 development, decreases 
the generation of Th2 cells but does not aff  ect the genera-
tion of IL-10–producing cells. Although we cannot exclude 
that under Th2 conditions, ICOS-L–induced IL-10 may de-
pend at least in part on IL-4, these data strongly suggest that 
the ICOS-L–driven induction of IL-10 and the generation of 
Th2 cells are independently regulated on maturing pDCs. In 
line with our fi  ndings, ICOS-defi  cient patients were found 
to have decreased numbers of IL-10–producing T cells but 
normal numbers of Th2 cells and IFN-γ–producing T cells 
(36). Furthermore, on the transcriptional level, it was dem-
onstrated that the induction of IL-10 can occur in the ab-
sence of IL-4–driven Th2 development (37). However, our 
study is in contrast to a recent publication showing that 
blocking ICOS-L inhibits the production of IL-10 as well as 
Th2 cytokines by CD45RO+ memory T cells cultured 
with pDCs, suggesting that there may be diff  erences in the 
role of ICOS costimulation in primary versus memory T cell 
responses (38).
IL-10–producing T cells induced by ICOS-L on matur-
ing pDCs have characteristics of T regulatory cells with the 
ability to suppress bystander T cell activation through the se-
cretion of IL-10. In recent years, there has been accumulat-
ing evidence that there may be a specialized role for pDCs 
in peripheral tolerance, although the molecular basis for this 
has not been identifi  ed. pDCs were shown to suppress in-
fl  ammatory responses to inhaled allergens (39), microbial 
  infections (40), and tumors (41), to promote allogeneic stem cell 
  engraftment (42), and to mediate tolerance to solid grafts by 
inducing T regulatory cells (43). Our study now identifi  es a 
specialized molecular pathway that intimately links maturing 
pDCs to the generation of T regulatory cells through ICOS-L. 
ICOS-L has been previously implicated in the generation of 
IL-10–producing T regulatory cells in both human studies 
(31) and mouse disease models (29, 30, 44). Furthermore, a 
specifi  c defect in T regulatory cell–mediated mucosal toler-
ance has been shown in ICOS-defi  cient (ICOS−/−) mice 
(45), and increased susceptibility to autoimmune disease has 
been described in ICOS-defi  cient patients (36). The fact that 
pDCs are intimately linked to the generation of IL-10–pro-
ducing T regulatory cells upon activation and diff  erentiation 
into mature DCs is in striking contrast to the fact that mDCs 
drive the generation of IL-10–producing T regulatory cells at 
immature stages and lose this ability upon maturation (11–13). 
These fi  ndings may suggest a specialized role for pDCs in 
immunoregulation during infection and infl  ammation.
There is indisputable evidence that pDCs can drive pro-
tective antiviral infl  ammation through their ability to produce 
type 1 IFNs, which promotes the function of bystander 
mDCs (46–48), B cells (49), T cells (50), and NK cells (51, 
52). However based on our fi  ndings, maturing pDCs have an 
intrinsic property to inhibit immune responses by inducing 
IL-10–producing T regulatory cells when directly presenting 
Ag to T cells. These IL-10–producing T regulatory cells may 
prevent excessive infl   ammation, which could damage the 
host. In support of our hypothesis, the depletion of pDCs 
during viral infection exacerbates immunopathology of the 
infected host (53), and the absence of IL-10 leads to uncon-
trolled lethal immune responses to infections (54).
In conclusion, we defi  ne the molecular pathway un-
derlying the specialized property of pDCs but not mDCs 
to generate IL-10–producing T regulatory cells at a mature 
  diff  erentiation stage. We show that in contrast to mDCs, 
pDCs are poised to express ICOS-L upon maturation, which 
directly leads to the generation of IL-10–producing regula-
tory T cells independently of Th2 or Th1 polarization. Our 
data provide the formal proof that pDCs and mDCs represent 
distinct DC subsets that evolved to perform diff  erent func-
tions in adaptive immunity.
MATERIALS AND METHODS
Media and reagents. For cell stimulation, we used 10 ng/ml IL-3 (R&D 
Systems), 2 μM CpG type A (2216), type B (2006), and type C (C274), 
1 μg/ml LPS (from Escherichia coli; 0111:B4; InvivoGen), 25 μg/ml poly(I:C) 
(InvivoGen), 1 μg/ml R848 (InvivoGen), γ-irradiated HSV-1 (KOS strain; 
10 PFU/cell), and the infl  uenza virus (PR8 strain; 10 PFU/cell). For CD40 
stimulation, we used CD40L-transfected L cells as previously described (9).
Generation of maturing pDCs and maturing mDCs. This study was 
approved by the Institutional Review Board for Human Research at the 
M.D. Anderson Cancer Center. pDCs were isolated from the buff  y coat of 
healthy adult volunteers as previously described (5). In brief, pDCs were fi  rst 
enriched by positive immunoselection using anti–BDCA-4 microbeads 
(Miltenyi Biotec) and were sorted by FACS (Aria; BD Biosciences) accord-
ing to their CD4+, CD123+, CD11c−, CD3−, CD14−, CD15−, CD16−, 
CD19−, and CD56− phenotype to reach >99% purity according to their JEM VOL. 204, January 22, 2007  113
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BDCA-2 expression. The sorted cells were seeded at a density of 105 
cells/200 μl of medium in fl  at-bottomed 96-well plates with each activation 
stimulus. For T cell coculture experiments, maturing pDCs were generated 
from pDCs by culturing with IL-3 in the presence of irradiated CD40L-
transfected L cells for 6 d or with 2 μM of type B CpG (2006) for 2 d. Im-
mature mDCs were generated from blood monocytes obtained from total 
PBMCs using anti-CD14 microbeads cultured for 5 d with GM-CSF and 
IL-4. Maturing mDCs were then generated by stimulating immature mDCs 
with LPS or CD40L-transfected L cells for 1 d.
Microarray analysis and bioinformatics. Total RNA was immediately 
isolated with the RNeasy kit (QIAGEN) and used to generate cDNA ac-
cording to the Expression Analysis Technical Manual from Aff  ymetrix, Inc. 
Complementary RNA samples were generated with the BioArray HighYield 
RNA Transcript Labeling kit (Enzo Life Sciences) and the human genome 
U133 plus 2.0 array (Aff  ymetrix, Inc.) according to the manufacturers’ 
  protocols. The scanned images were aligned and analyzed using GeneChip soft-
ware (Microarray Suite 5.0; Aff  ymetrix, Inc.) according to the manufactur-
er’s instructions. The signal intensities were normalized to the mean intensity 
of all of the genes represented on the array, and global scaling (scaling to all 
probe sets) was applied before performance of the comparison analysis.
Analyses of surface ICOS-L expression. To evaluate surface ICOS-L 
expression, maturing pDCs and mDCs were stained with PE-labeled anti–
ICOS-L mAbs (eBioscience) or isotype-matched control mAbs after being 
harvested at diff  erent times during the culture and subjected to FACS (FACS-
Calibur; BD Biosciences). For comparison, the cells were also stained with 
mAbs to CD80 and CD86 (both from BD Biosciences).
CD4 T cell stimulation. Fresh peripheral blood naive CD4 T cells (>99% 
pure) were isolated using a CD4 T cell isolation kit (T cell Isolation Kit II; 
Miltenyi Biotec) followed by cell sorting as CD4+ CD45RA+ CD45RO− 
CD25− Lineage− (CD14−, CD16−, CD20−, CD56−,  γδTCR−, and 
BDCA2−) cells as previously described (33). Alternatively, fresh cord blood–
derived naive CD4 T cells were isolated from fresh cord blood by using 
T cell Isolation Kit II as previously described (11). This procedure was 
  followed by a depletion of CD25+ cells to deplete T regulatory cells. The 
resulting cells were routinely >96% of CD4+ CD45RA+ CD45RO− 
CD25− T cells. 2 × 104 freshly purifi  ed allogeneic naive CD4 T cells were 
then cultured with maturing pDCs or maturing mDCs (DC/T cell ratio of 
1:5) in round-bottomed 96-well culture plates for 6 d. We used 50 μg/ml 
anti–ICOS-L mAb (eBioscience) and a combination of 5 μg/ml anti-CD80 
and 10 μg/ml anti-CD86 mAbs (R&D Systems) in our cultures. Mouse 
IgG1 was used as an isotype control. For IL-4–blocking experiments, 10 μg/ml 
anti–IL-4 mAb (MP4-25D2; BD Biosciences) was added to the cultures. For 
restimulation experiments, primed CD4+ T cells collected after 6 d were 
  recultured with monocytes from the same allogeneic donor used for priming 
(monocyte/T cell ratio of 1:1) for 3 d.
Analyses of T cell cytokine production. Primed CD4 T cells were col-
lected and washed after 6 d of primary stimulation with DCs. For the detec-
tion of cytokine production in the culture supernatants, the T cells were 
restimulated with 5 μg/ml of plate-bound anti-CD3 (OKT3) and 1 μg/ml 
of soluble anti-CD28 mAb at a concentration of 106 cells/ml for 24 h. The 
levels of IL-10, -4, -5, -13, TNF-α, and IFN-γ were measured by ELISA 
(all kits were obtained from R&D Systems). For intracellular cytokine pro-
duction, the primed CD4 T cells were restimulated with 50 ng/ml PMA 
plus 2 μg/ml ionomycin for 6 h. 10 μg/ml brefeldin A was added during the 
last 2 h. The cells were stained with the combination of fl  uorochrome-
  labeled mAbs to IL-10, -4, and IFN-γ.
Generation of human ICOS-L–expressing L cells. Human ICOS-L–
expressing L cells were generated by transducing parental CD32 L cells with 
a mouse stem cell virus–based retroviral vector (pMIGW2) carrying the full-
length human ICOS-L coding sequence (GenBank EMBL/DDBJ accession 
no. NM_015259). A high level and stable expression of human ICOS-L in 
the transduced cells were confi  rmed by FACS analysis with PE-labeled anti–
human ICOS-L mAbs (eBioscience).
Suppressor assay. In direct coculture experiments, 4 × 104 naive CD4 T 
cells were cultured in round-bottomed 96-well plates with 4 × 104 alloge-
neic monocytes in the presence of equal numbers of syngeneic CD4 T cells 
primed by pDC-derived DCs. After 6 d of culture, 1 μCi [3H]thymidine 
was added to each well, and cellular incorporation was determined after 12 h. 
In some experiments, 10 ng/ml of neutralizing anti–IL-10 mAb plus 10 ng/ml 
anti–IL-10R mAb (R&D Systems) or recombinant human IL-10 was added.
Online supplemental material. Fig. S1 shows the rapid upregulation of 
ICOS on naive T cells cultured with maturing pDCs and maturing mDCs. 
Fig. S2 shows that ICOS-L on maturing pDCs induces IL-10 production in 
cultured naive cord blood–derived T cells. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20061660/DC1.
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